Psoralen photochemotherapy (PUVA) is the combined treatment of skin disorders with a photosensitizing drug (Psoralen) and UltraViolet A radiation. The introduction of PUVA therapy has arguably been the most important development in dermatology over the past 30 years and from the first days of the treatment being introduced in the UK, British medical physicists were an integral part of the effort to establish it. Medical physicists have contributed to this development in a number of ways, from designing irradiation units in the early days of the technique, through to collaborating with dermatologists in prosecuting clinical and experimental studies aimed at improving patient outcomes. That the dose of UVA radiation is administered quantitatively, and not qualitatively, has probably been the single most important contribution made by several medical physicists over this period. However, despite concerns that were expressed almost 30 years ago about the accuracy with which UVA doses are administered to patients, the medical physics community still has some way to go before we can be satisfied that statements about UVA irradiance and dose can be made with confidence.
Introduction
Treatment of skin diseases using artificial sources of ultraviolet (UV) radiation has been practised in hospitals since the early part of the 20th century following the pioneering work of the Danish physician Niels Finsen (Serup 2003) . For most of that time, treatment was by exposure to UV lamps where the therapeutic waveband was largely in the UVB (280-315 nm) region, and often used in combination with agents applied topically such as coal tar or dithranol (Scott 1967) . But in the early 1970s a new type of phototherapy became available known as psoralen photochemotherapy, commonly referred to as PUVA.
Psoralen photochemotherapy is the combined treatment of skin disorders with a photosensitizing drug (Psoralen) and UltraViolet A radiation (315-400 nm). Psoralens are naturally occurring plant compounds and their therapeutic potential for the treatment of the socially disfiguring disease vitiligo has been recognized for many thousands of years (Pathak and Fitzpatrick 1992) . Photochemotherapy using synthetic psoralen compounds such as 8-methoxypsoralen (8-MOP) or, to a lesser extent, 5-methoxypsoralen (5-MOP) was introduced in the 1970s (Roelandts 1991) .
The results from early studies were not especially encouraging due to the rather low output of the UVA lamps available at that time (Roelandts 1991) . In 1974 a group from Harvard Medical School published a seminal piece of work (Parrish et al 1974) that changed the practice of dermatology worldwide and that was made possible by the availability of fluorescent lamps emitting UVA radiation at sufficient intensity to allow effective treatment in practicable irradiation times (Pathak and Fitzpatrick 1992) . The treatment quickly caught on and in the UK the first published studies from dermatologists based in Dundee (Lakshmipathi et al 1977) and Newcastle and London (Rogers et al 1979) confirmed the efficacy of the treatment. This treatment is now widely used as a second-line form of therapy and by 1990 was available in around 100 dermatology centres in the UK .
But right from the first days of PUVA therapy, British medical physicists were an integral part of the effort to establish the treatment and this is the story of that involvement told from the perspective of someone who was there at the beginning and has contributed to the development of this therapy over the past 30 years.
In 1926, Oscar Bernhard wrote in his book 'Light Treatment in Surgery': "For medical purposes carbon arc lamps show deficiencies which can only be done away with by the united work of medical men and physicists." A moment of good fortune for me in this story was, in 1983, meeting Peter Farr who was a registrar in dermatology at Dryburn Hospital in Durham, where I was then working. Peter and I brought our respective expertise in medicine and physics together in equal measure to address clinical challenges in the development of PUVA and have continued to collaborate since, as the liberal sprinkling of references in this review will reveal. (There was perhaps more than just good fortune in this partnership in that Peter's father was the late Frank Farr who, for many years, was Head of Medical Physics in Birmingham.)
Diseases that respond to PUVA
Psoriasis, a disease characterized by red, scaly plaques and affecting about 2% of the population, is the skin disease most frequently treated by PUVA. However there are many other disorders that show partial or complete response to PUVA and these include vitiligo, eczema, lichen planus, graft-versus-host disease, cutaneous T-cell lymphoma (mycosis fungoides), and photosensitive disorders such as polymorphic light eruption, actinic prurigo and chronic actinic dermatitis (Norris et al 1994) .
Pharmacology and mechanism of action
When PUVA therapy was introduced, the dose of 8-MOP was calculated based on body weight and given in a standard dose of 0.6 mg kg −1 (Norris et al 1994) . As nuclear medicine physicists know, body surface area shows a higher correlation with plasma volume than does body weight and so we suggested that a more appropriate dosing of 8-MOP might be achieved using a system based on surface area, and provided evidence (Sakuntabhai et al 1995) that this method of dosing at 25 mg m −2 improved the therapeutic effect of PUVA in psoriasis. Following oral administration of 8-MOP, absorption and resulting plasma concentrations show considerable variation between subjects, but UVA exposure is given usually 2 h after ingestion at the average time of peak plasma concentration (Stevenson et al 1981) . PUVA may also be given using topical psoralen, either painted onto the skin surface or, more frequently, using a bath delivery system in which the patient soaks for 15 min in a weak psoralen solution e.g. 3.75 mg l −1 of 8-MOP, followed immediately by UVA exposure. Significant concentrations of psoralen in plasma are not achieved with topical psoralen.
Psoralen molecules, when activated by UVA radiation form cross-links between adjacent strands of DNA, thus interfering with DNA and cellular replication. Although it has been assumed that this is the mechanism of action of PUVA in disorders associated with increased cell division (such as psoriasis), PUVA also has other important actions on the skin, including induction of pigmentation and epidermal hyperplasia, suppression of certain components of the immune system and release of reactive oxygen and free radicals which damage cell membranes and cytoplasmic structures.
Treatment apparatus
It was in the design and construction of UVA irradiation units that medical physicists helped pioneer the introduction of PUVA to the UK.
The first unit to be built was in the Medical Physics Department at Ninewells Hospital in Dundee under the direction of Leslie Mackenzie. This unit, shown in figure 1, contained a mixture of 60 cm (20 W) and 120 cm (40 W) UVA lamps, delivered an approximate irradiance at the skin surface of 2 mW cm −2 and entered clinical practice in 1975 (Lakshmipathi et al 1977) .
At this time, I was a medical physicist at the Kent and Canterbury Hospital and designed a different type of unit that was constructed by Hanovia Lamps Ltd (Slough). The UV source used was a single medium pressure mercury arc lamp, 150 cm in length, surrounded by a glass outer cylinder and operated from a 5 kW electrical supply (figure 2). The radiation was filtered by UV transmitting ('black glass') filters, such that 93% of the UV emission spectrum lay in the 365 nm characteristic mercury line. The patient was rotated at 3 revolutions per minute approximately 10 cm in front of the filter. The irradiance at this distance was 8 mW cm
with an effective irradiance of approximately 1.7 mW cm −2 due to the rotation. We treated our first patient on 12 November 1976 but as history has shown, spinning patients in front of UV lamps never caught on! The first whole-body commercial PUVA unit manufactured in the UK was distributed by Rank Stanley Cox (Ware, Hertfordshire) and is illustrated in figure 3 . By the mid 1980s a wide range of commercial apparatus designed for treating partial or whole body disease was available in the UK (Mountford 1986 ). However, the undoubted leader in the manufacture of these units in Europe now, and since the treatment was first introduced, has been the German company Waldmann (www.waldmann-medizintechnik.com).
Ultraviolet measurement and dosimetry
Shortly after the introduction of PUVA therapy in the early 1970s, the protagonists of the treatment (Wolff et al 1977) stressed that " . . . careful attention to dosimetry is essential and . . . the dosimetry system is a key to both the effectiveness and safety of PUVA." These authors recommended that UVA exposure of the patient be expressed in radiometric units; the intensity (or irradiance) of the radiation beam is measured in milliwatts per square centimetre (mW cm −2 ) and the prescribed dose (or radiant exposure) is expressed in joules per square centimetre (J cm −2 ). In 1985, Leslie Mackenzie in Dundee published an important paper that explained clearly why UVA radiation should be measured in photochemotherapy (Mackenzie 1985) : to allow consistent radiation exposure of patients over many months and years within a local department; and to allow the results of irradiations made in different departments to be published and compared.
He stressed that it is important to distinguish between these two objectives. The first requires precision, or reproducibility. The dosemeter is used as a monitor to give a reference measurement and so it needs to be stable. Accuracy, that is, absolute calibration against some accepted standard, is not essential. The second objective requires both precision and accuracy. Here the dosemeter must not only be stable from one day to the next, but also the display (for example, in radiometric units of mW cm −2 ) must be traceable to absolute standards. In 1978, I published a review of UVA doses that had been quoted in the PUVA literature up until then and which showed a large variation in typical doses per treatment and the cumulative dose for clearance of psoriasis (Diffey 1978) . Part of the variation was attributed to a poor understanding and uncertain approach to UV dosimetry for reasons that Tony Challoner, a physicist at the Institute of Dermatology in London, and I had proposed in an earlier paper (Challoner and Diffey 1977) . We argued that collaboration between radiotherapists and physicists had led to rationalization of radiotherapy doses and suggested a similar alliance between dermatologists and physicists might be equally beneficial in PUVA therapy.
We recognized that an important property of UV detectors for use at relatively short distances from extended arrays of fluorescents lamps was a wide angle of response. If this could be combined with a wavelength-independent spectral response, we could have the ideal UV detector . Consequently, we persuaded Rank Hilger Ltd (Margate, Kent), who was then manufacturing thermopiles with a limited field of view, to construct a similar instrument with a wide field of view exhibiting a cosine-weighted response (figure 4).
Whilst this device exhibited a good spectral and angular response, it suffered from the same drawbacks as other thermopiles available in the 1970s in that they were hand-made, expensive and fragile, and not suited to regular use for monitoring lamp output in busy dermatology departments. Consequently we adapted a simple photoconductive cell that we had previously designed as general light meter in dermatology (Diffey et al 1976) by incorporating an ultraviolet-transmitting, visible-light absorbing 'black glass' optical filter to produce a detector specifically for use in PUVA (Diffey and Miller 1978) . This detector exhibited a peak spectral response in the UVA at 370 nm, and fell to zero response at 290 and 420 nm, but unfortunately also had a response in the near infrared from 700 to 850 nm as a consequence of the cadmium sulphide (CdS) cell we had used as the sensor. Consequently an appropriate correction to the sensor reading had to be made to account for the infrared component of lamps.
To overcome this problem we persuaded Rank Hilger Ltd to adopt the idea of manufacturing a solid-state 'PUVA meter' but to replace the CdS cell with a gallium arsenide phosphide (GaAsP) photodiode, which exhibits no infrared response and when suitably optically filtered results in a true UV-selective detector. This the company did and the resulting device-the Uvichek-has been widely used for many years in dermatology and medical physics departments.
When detectors such as the Uvichek became readily available, we evaluated four different commercial models and found wide variations in absolute calibration, angular response and spectral response (Stobbart and Diffey 1980) . The directional, or angular, response is an important aspect of ultraviolet radiometer performance, and Colin Martin in Glasgow and Steve Pye in Edinburgh have investigated this extensively in a series of elegant experimental and theoretical studies (Martin et al 1999 .
Dosimetric inter-comparisons
Because of the problems highlighted with UV dosimetry (Diffey 1978) , Tony Challoner and I secured funding from the Psoriasis Association and in 1978 visited nine PUVA centres in England to carry out a dosimetric inter-comparison. We found a wide variation in accuracy of the UVA meters encountered, with a difference of over 300% in relative sensitivity compared with a reference instrument .
With the help of Belgian dermatologist Rik Roelandts, I carried out a similar survey in Belgium where dermatologists were invited to bring their UVA meter to a national meeting, during which its response was compared with a reference meter. Thirty-one meters (5 different models) from 29 Belgian PUVA centres were compared, yielding similar results as above with a 2.8 factor in relative sensitivity (Diffey and Roelandts 1986) . At a similar event in Lille, 31 UVA meters in use in French PUVA centres were inter-compared and here a four-fold range in sensitivity was found (Roelandts et al 1988) .
The most recent survey in the UK was carried out by Jim Lloyd, a medical physicist in Newcastle (Lloyd 2004) . In this inter-comparison the same UV meter with two detectors (for UVA and UVB) was calibrated by seven UK medical physics departments. For the UVA and narrow-band UVB (TL-01, Philips Lighting, The Netherlands) calibrations the ratio between the maximum and minimum sensitivity factor was 1.28 and 2.74, respectively. These results are a cause for concern, particularly for measurement in narrow-band UVB phototherapy. A meter calibrated for TL-01 at one centre and giving a reading of 5 mW cm −2 in a phototherapy cabin could read up to 14 mW cm −2 in the same position if calibrated at another centre.
UVA radiometer calibration
The established technique for calibrating UVA meters used in photochemotherapy is to measure the spectral irradiance from a bank of UVA lamps with the same spectral output as those that are used for treatment, sum the spectral irradiance across the UVA waveband and derive the absolute irradiance. Calibration of a UVA dosemeter simply involves removing the spectroradiometer, placing the entrance aperture of the sensor at the same point as the input optics of the spectroradiometer and adjusting the meter display so that it reads the irradiance determined spectroradiometrically (Diffey 1992) . Andrew Coleman (St Thomas' Hospital, London) has described a calibration system that is claimed to provide increased accuracy in the measurement of the irradiance responsivity appropriate for UV meters used with broadband, extended sources i.e. fluorescent lamps (Coleman et al 2000) . The single wavelength responsivity of the test meter is obtained in the wavelength range 250-400 nm by inter-comparison with a transfer standard meter in a narrow, monochromatic beam. The effective responsivity of the test meter, when used with broadband extended sources, is calculated using the measured spectral and angular response of the meter and tabulated data on the spectral and spatial characteristics of the source radiance. The uncertainty in the effective responsivity, independent of the source variability, is estimated to be 10% (at 95% confidence).
Determining patient UVA irradiance
Two measurement methods are in common use for estimating the notional UVA irradiance at the patient's skin surface; the so-called direct method, which requires a cabin occupant to hold the meter and note the reading, and the indirect method, in which the meter is supported mechanically inside the cabin and the operator remains outside (Diffey and Hart 1997 , Moseley 2001 , Martin et al 2003 , Taylor et al 2002 . Harry Moseley (Dundee) has probably tackled this subject more thoroughly than others and in 1995 steered a group of Scottish dermatologists to agree on a set of dosimetry guidelines (Moseley 2001) .
A number of UK medical physicists have contributed to measurement techniques leading to estimates of patient irradiance. In an early study, Peter Mountford and colleagues (Canterbury) described a system for remotely mounting the UVA detector inside the cabin and so obviate the need for an operator to make the measurements of irradiance directly (Mountford et al 1983) . Keith Langmack (Cambridge) developed a theoretical model that incorporated the multiple reflections of UVA radiation from the non-perfect reflectors behind the lamps and the self-shielding of the patient inside the irradiation cabin to determine the factor that needs to be applied to the irradiance measured when the cabin is empty to give the irradiance to be expected when a patient is present. He was able to show that calculated UVA irradiances were in good agreement with those measured (Langmack 1998) .
More recent approaches include that from Catherine Fulljames and Anne Welsh (Gloucester/Cheltenham) who constructed a phantom of expanded polystyrene blocks with an embedded probe and made measurements to verify the equivalence of human and phantom cabin occupancy. They found that the irradiance measured with the phantom in the cabin fell within the values measured with human occupancy (Fulljames and Welsh 2000) . Garry Currie and colleagues (Glasgow) described a technique for automated ultraviolet dosimetry within whole-body phototherapy cabins (Currie et al 2001) . This involved using a dual-head detector system that permits simultaneous assessment of irradiance levels and radiant intensities from individual lamps. The device has the advantage of enabling measurements to be made without the need for a person to be present in the cabinet. The data obtained enable failed lamps to be detected and peak values can be related to radiant intensities of individual lamps.
There are two broad factors that influence the UVA exposure dose at different body sites from photochemotherapy equipment; geometric factors associated with the design of the apparatus and topological factors associated with the shape of the patient. We first studied this using photosensitive film dosimeters attached to the surface of a manikin and showed that a large fraction of the body surface area receives more than 70% of the maximum dose although shaded areas, such as the axillae and groin, receive a much smaller fraction.
The most recent guidelines for the dosimetry and calibration of UV meters used in photochemotherapy have been produced jointly by medical physicists and dermatologists and are available in a publication co-ordinated by David Taylor, Gloucester (Taylor et al 2002) .
Treatment regimens
For psoriasis, PUVA treatment regimens are now well established (Norris et al 1994) . In the early days of PUVA, treatment for psoriasis in the UK was given usually three times per week (Lakshmipathi et al 1977 , Rogers et al 1979 . However, as PUVA erythema does not reach a maximum until at least 72 h after exposure, treatment on a Monday, Wednesday and Friday, leaving only 48 h between some exposures, considerably increases the risk of burning. Consequently, the usual practice now is twice-weekly treatment (Norris et al 1994) . This has been shown to be effective for psoriasis (Sakuntabhai et al 1993c) , is considerably more convenient for patients than 3-times-weekly treatment and allows greater efficiency of operation of a PUVA unit.
The initial UVA exposure dose is often based on the sun-reactive skin type of the patient. However, the additional factor of variable skin photosensitivity due to differences between patients in psoralen pharmacokinetics (Sakuntabhai et al 1993b) means that skin typing is even Figure 5 . The phototesting template used for determining a patient's minimal phototoxic dose prior to starting PUVA treatment (Diffey et al 1993) .
less useful as a method of prediction of erythemal sensitivity for PUVA compared with UVB phototherapy. Measurement of each patient's minimal phototoxic dose (MPD), which is the smallest dose of UVA required to achieve erythema in psoralen-sensitized skin, at the start of a course of treatment allows high-dose treatment regimens to be used without increased risk of burning, and results in faster clearance of psoriasis. The MPD may be measured by exposing small areas of normal skin (e.g. 1 cm diameter sites) on the forearm or back to increasing doses of UVA (e.g. 1, 2, 4 and 8 J cm −2 for oral 8-MOP treatment), and then observing which, if any, of the sites become erythematous at 72 h. The traditional way to achieve this is to expose test sites for varying times at a fixed distance from a UVA source; a commercial apparatus is available that uses electrically-operated shutters that close at predetermined times.
An alternative approach is to keep irradiation time fixed and vary the UVA irradiance at each test site. This is the basis of a device that we described (Diffey et al 1993) and the 'phototesting template' consists of a metal foil with 4 apertures of 10 mm diameter mounted in pliable polyurethane. One aperture is open and the other three each incorporate a grid of hexagonal holes of differing size that attenuate the UVA, resulting in relative intensities at the skin surface of 1, 2, 4 and 8 (figure 5). Thus a single exposure of, for example, 8 J cm −2 would allow the MPD to be determined as 1, 2, 4, 8 or >8 J cm −2 . Whole-body treatment is given using between 40 and 70% of the MPD. Doses are increased usually weekly by between 10 and 40% to maintain the response to treatment as the skin adapts by pigmentation and epidermal thickening. Using a twice-weekly protocol with MPD measurement to choose the starting dose, it is typically possible to clear psoriasis with a median of 17 exposures and a cumulative UVA dose of around 70 J cm −2 (Gordon et al 1999) . The response to treatment is quite variable, however, and some patients will clear faster than this, whilst others show a slower response. For topical (bath) PUVA, smaller UVA doses are used, as the skin is more photosensitive than with oral PUVA. Typical starting doses are 0.2-0.5 J cm −2 (Halpern et al 2000) . Once clearance of psoriasis has been achieved, it used to be common practice to continue with PUVA for a variable period to maintain remission. With the long-term side effects of PUVA now well defined (see later), many dermatologists prefer to avoid maintenance treatment wherever possible.
Spectrum of therapeutic response
In an ideal situation the therapeutic action spectra for specific diseases would be determined and matched to UV radiation sources with appropriate emission spectra. When PUVA therapy R238 Review Figure 6 . The cylindrical irradiation chamber housing 15 × 20 W fluorescent lamps designed for determining the action spectrum for clearance of psoriasis by PUVA . The line drawing omits the protective outer casing and demonstrates the position of a handgrip.
was established the sources used were almost invariably UVA fluorescent lamps emitting a continuous distribution from about 310 to 400 nm and peaking at around 352 nm. The choice of this particular spectral power distribution was not based on knowledge of the action spectrum for healing psoriasis but on the availability of high intensity UVA lamps that had been developed for the printing industry.
Action spectroscopy in most photobiological research involves the use of an irradiation monochromator to deliver a narrow waveband of radiation. Technical factors limit the irradiation field with this technique to less than about 10 cm 2 and this small field size presents problems when treating lesions of psoriasis over several weeks. An alternative technique, and the one we adopted , was to use three cylindrical arrays of fluorescent lamps (see figure 6), each with a different emission spectrum peaking at 325 nm, 352 nm and 370 nm respectively, and to deduce the therapeutic action spectrum by a process of induction.
We showed that the effectiveness of UV radiation decreased exponentially with increasing wavelength throughout the UVA waveband, such that radiation at 320 nm was an order of magnitude more effective than 360 nm . In a related study using a much smaller number of patients and two narrow wavebands from an irradiation monochromator, a group from Vienna showed that PUVA with 335 nm radiation was twice as effective as with 365 nm in terms of the cumulative dose required for clearance (Br ucke et al 1991) .
Psoralen erythema
Following oral administration of 8-MOP, the cutaneous photosensitivity to UVA parallels the plasma psoralen concentration; maximally sensitive after around 2 h and gradually returning to normal by 8-12 h. The photosensitivity from topical psoralen lasts for a much shorter period of less than 4 h. Unlike UVB erythema (or UVA erythema without psoralen), PUVA erythema has a delayed onset, being first noticeable 24-48 h after irradiation, and does not reach maximum intensity until 72-96 h (Ibbotson and Farr 1999) .
We showed that the erythemal sensitivity of the skin, assessed as the MPD, varies by a factor of at least 10 between patients (McLelland et al 1991) and in a subsequent study were able to demonstrate that this is related to both plasma psoralen concentration and inherent UVA sensitivity (Sakuntabhai et al 1993b) .
Unlike UVB erythema, where doses above the minimal erythema dose (MED) cause severe burning easily, we were able to show using reflectance spectroscopy that PUVAinduced erythema has a much shallower dose-response slope than UVB-induced erythema, and that 2 or 3 times the MPD results only in mild or moderate erythema when psoralen has been given orally (Cox et al 1989) . Burning may happen more easily with topical psoralen, however.
Side effects
The main short-term side effects of PUVA are erythema and nausea. PUVA erythema has a delayed onset compared with UVB erythema, can persist for a week or more and may be associated with severe itching, blistering and local skin pain. The risk of burning is minimized if care is taken not to treat patients who have any residual erythema from the previous treatment. Once symptomatic erythema has developed, emollients and topical corticosteroids may aid resolution. Severe erythema may be followed by the development of new lesions of psoriasis arising within areas of damaged skin.
Nausea is quite common with oral 8-MOP, lasting 1-4 h after ingestion. In some patients, this problem can be overcome if the drug is taken with a light meal. For the 5% of patients in whom nausea prevents the use of 8-MOP, 5-MOP may be substituted, although this drug may be less effective at clearing psoriasis.
Many patients who have received PUVA in high doses over long periods will have some signs of skin damage. Multiple, small hyperpigmented lesions, termed PUVA freckles (or PUVA lentigines) are seen in up to 70% of high-dose patients. They have not been shown to have malignant potential, but may be perceived by some patients as a cosmetic problem. More worrying is the development of warty, keratotic lesions (PUVA keratoses), usually up to 1 cm in diameter, which may show pre-malignant features on histological examination. It is now clearly established that long-term PUVA treatment results in an increased risk of cutaneous squamous-cell carcinoma (Stern and Laird 1994) . This risk has shown to be dose-dependent: a cumulative UVA dose received through PUVA of <500 J cm −2 is unlikely to result in significant risk; above 1000 J cm −2 is associated with definite risk, and around 50% of patients who have received >2000 J cm −2 will have PUVA keratoses or squamous carcinoma (Lever and Farr 1994) . In some centres, malignant tumours have occurred on the male genitalia and it is now recommended that this area should be protected by clothing whenever possible during a course of treatment. There has also been one report suggesting that PUVA treatment may be associated with an increased risk of malignant melanoma (Stern et al 1997) . The very real risk of serious skin damage through PUVA emphasizes the importance of accurate dosimetry and careful selection of patients for PUVA treatment.
PUVB and UVA
PUVA is, of course, the combination of psoralens with UVA radiation. An important question to ask is whether combining psoralens with another waveband of UV radiation might be equally or more effective and so we studied the effect of oral 8-MOP in combination with narrow-band UVB (311 nm) radiation in ten patients with psoriasis affecting their forearms (Sakuntabhai et al 1993a) . We found that psoralen in combination with UVB had a therapeutic effect in terms of time to clearance that was greater than the response to UVB alone but not to an extent that indicated this combination should replace PUVA.
UVA sunbeds are widely used by patients with psoriasis in an attempt to treat their skin disease (Turner et al 1998) , yet there is little evidence that UVA therapy improves psoriasis, and the long-term risks of sunbed exposure are not known. In a randomized, placebo-controlled study of UVA sunbed therapy for psoriasis we showed that a short course of UVA sunbed treatment does improve psoriasis in some patients, but that the degree of improvement is small (Turner et al 2000) . Consequently, we would advise patients to 'save' their skin for hospital-based UV phototherapy, which is at least known to be effective.
Preventing unnecessary UVA exposure
The need to shield the face during PUVA therapy is well recognized since the face receives frequent exposure to sunlight and is the most common site for skin cancers, and to prevent tanning which some psoriasis sufferers find distressing to explain away, particularly during the winter months. This can be achieved with topical sunscreens, which can be messy and time consuming to apply, an opaque material (e.g. towel) over the face, which many patients find claustrophobic, or a UV-opaque face visor, which is the preferred option. Visors designed for industrial use can be used (Dawe et al 1996) or else a disposable UV-opaque face mask that can be cut to shape (Steele and Diffey 1997) and which has been shown to be effective and well-tolerated by patients (Caird and Rogers 1999) .
Patients who are treated with oral PUVA receive a known dose of UVA during their treatment and then leave the department. But the skin remains photosensitive over the following 8-12 h and so patients will also receive an unknown and variable exposure from solar UVA depending on climatic and other factors for the remainder of the day. By developing a model that incorporated solar spectral irradiance with behaviour outdoors and the pharmacokinetics of 8-MOP, I showed that patients treated during the summer months in the UK may well receive a solar UVA dose, principally to the hands and face, that is comparable with, or even in excess of, the UVA dose received during treatment and so should be advised about limiting their outdoor exposure on treatment days (Diffey 1981) . In the winter months, no unduly restrictive precaution need apply. These predictions were in good agreement with the results of an experimental study that Harry Moseley (then in Glasgow) and I carried out, where we found a median solar UVA dose on their treatment day of around 1 J cm −2 in 56 patients monitored with personal UV film badges between July and September 1980, with a range of 0.2 to 7 J cm −2 (Moseley et al 1981) .
Eye protection in PUVA
One of the potential complications of long-term PUVA therapy with oral psoralens is the possibility of inducing cataracts, a fear that arose from animal experiments (Cloud et al 1961, Freeman and Troll 1969) . As a result, close fitting UV-opaque goggles are essential during treatment and patients are advised to wear UV-opaque spectacles whenever they are outdoors over the following 12-24 h (www.bad.org.uk/healthcare/guidelines/puva.asp).
Medical physicists have played a leading role in evaluating the optical properties of protective eyewear and recommending limits of acceptability. In general, sunglasses sold in retail outlets in the UK conform to British Standard BS2724. However this standard is not stringent enough to meet the protection of psoralen sensitized eyes (Moseley et al 1988) . Patients should be advised to look for those sunglasses that are marked UV400. The lenses in these sunglasses block all UV wavelengths below 400 nm and should be the only type recommended to PUVA patients.
Patients who normally wear prescription spectacles and wish to continue wearing these can have them coated with a material that is visibly clear but opaque to both UVA and UVB (Moseley and Jones 1990, Moseley and Perkins 1992) . Only plastic lenses can be coated but these comprise almost all new prescription spectacles in the UK. For those patients who do not wear prescription spectacles, low cost safety spectacles in clear polycarbonate, which is opaque to all UV wavelengths, are readily available.
The ideal method for determining if spectacles are suitable for protecting psoralensensitized eyes is to measure the spectral transmission on a wavelength-by-wavelength basis in a spectrophotometer (Davey et al 1981) and to compare the transmission values at a number of wavelengths with the transmission limits recommended by Moseley et al (1988) .
A simpler method, and one which is unlikely to lead to spectacles with inappropriate optical qualities being accepted, is to measure the amount of UVA radiation transmitted through the lens with the lamps used for PUVA therapy and a handheld UVA meter (Diffey and Miller 1980) . If the meter reads between 10 and 20 mW cm −2 without the lens in place, the reading needs to fall to at least 0.2 mW cm −2 and preferably below 0.1 mW cm −2 in order for the spectacles to provide adequate protection (Mountford 1990 ).
Conclusion
The introduction of PUVA therapy has arguably been the most important development in dermatology over the past 30 years. Medical physicists have contributed to this development in a number of ways, from designing irradiation units in the early days of the technique, through to collaborating with dermatologists in prosecuting clinical and experimental studies aimed at improving patient outcomes. That the dose of UVA radiation is administered quantitatively, and not qualitatively, has probably been the single most important contribution made by several medical physicists over this period. However, despite concerns that were expressed almost 30 years ago about the accuracy with which UVA doses are administered (Diffey 1978) , the medical physics community still has some way to go before we can be satisfied that statements about UVA irradiance and dose can be made with confidence (Lloyd 2004) .
